40391-99-9Relevant articles and documents
-
Kabachnik,M.I. et al.
, (1978)
-
Efficient synthesis of pamidronic acid using an ionic liquid additive
Grün, Alajos,Nagy, Dávid Illés,Garadnay, Sándor,Greiner, István,Keglevich, Gy?rgy
, p. 475 - 478 (2016)
An efficient method was developed for the synthesis of pamidronic acid involving the reaction of β-alanine with three equivalents of phosphorus trichloride and two equivalents of phosphorous acid at 75 °C in the presence of 0.3 or 0.6 equivalents of [BMIM][PF6] as an additive.
The synthesis of hydroxymethylenebisphosphonic- (dronic-) and acyl-ethoxycarbonyl-methylphosphonate derivatives
Für, Csilla Sepsey,Grün, Alajos,Gulyás, Kinga V.,Keglevich, Gy?rgy,Szalai, Zsuzsanna,Zahár, Róbert
, (2021/12/23)
Recent results on the synthesis of substituted hydroxymethylenebisphosphonic acids (A and B), as well as acylated ethoxycarbonyl-methylphosphonate derivatives (C and D) are summarized. In the first part, solvent mixtures were applied in the preparation of known dronic acids, while in the second series of experiments, new acyl species were synthesized.
Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis
Savino, Salvatore,Toscano, Annamaria,Purgatorio, Rosa,Profilo, Emanuela,Laghezza, Antonio,Tortorella, Paolo,Angelelli, Mariacristina,Cellamarea, Saverio,Scala, Rosa,Tricarico, Domenico,Thomas Marobbio, Carlo Marya,Perna, Filippo,Vitale, Paola,Agamennone, Mariangela,Dimiccoli, Vincenzo,Tolomeo, Anna,Scilimati, Antonio
, p. 184 - 200 (2018/09/18)
Bisphosphonates such as zoledronic, alendronic and risedronic acids are a class of drugs clinically used to prevent bone density loss and osteoporosis. Novel P-C-P bisphosphonates were synthesized for targeting human farnesyl pyrophosphate synthase (hFPPS) and human geranylgeranyl pyrophosphate synthase (hGGPPS), key enzymes of the mevalonate pathway, and capable of anti-proliferative action on a number of cell lines (PC3, MG63, MC3T3, RAW 264.7, J774A.1, bone marrow cells and their co-colture with PC3) involved in bone homeostasis, bone formation and death. Among sixteen compounds, [1-hydroxy-2-(pyrimidin-2-ylamino)ethane-1,1-diyl]bis(phosphonic acid) (10) was effective in reducing PC3 and RAW 264.7 cell number in crystal-violet and cell-dehydrogenase activity assays at 100 μM concentration. 10 reduced differentiated osteoclasts number similarly with zoledronic acid in osteoclastogenesis assay. At nanomolar concentrations, 10 was more effective than zoledronic acid in inducing mineralization in MC3T3 and murine bone marrow cells. Further, 10 significantly inhibited the activity of hFPPS showing an IC50 of 0.31 μM and a remarkable hydroxyapatite binding of 90%. Docking calculations were performed identifying putative interactions between some representative novel bisphosphonates and both hFPPS and hGGPPS. Then, 10 was found to behave similarly or even better than zoledronic acid as a anti-resorptive agent.